One step closer to personalized medicine

On September 21-23, 2015, the p-medicine consortium composed of 19 partner organisations from all over Europe and Japan came together for their final project meeting in Homburg/Saar, Germany. During the meeting, the project's final achievements were presented to representatives of the European Commission, the local government as well as interested companies, research institutions and patient/parents groups.

The project’s research resulted in a series of computer-based tools, which will help cancer patients to better understand the nature of their disease and support clinicians in finding the right treatment for the individual patient by analyzing ‘big data’ from individual patients. In the end, these tools will help not only to facilitate the communication between doctors and patients and guide them to make decisions about the patient’s treatment together but will help researchers to detect new knowledge out of shared and joined health data combined with open access data.

Prof. Norbert Graf, coordinator of p-medicine, states in an interview: "The p-medicine project is facing the situation that even large diseases like breast cancer are divided into different subtypes. And each of these subtypes needs different treatment. To get these treatments to the correct patient, we need tools that are developed in p-medicine."

In the meeting's "public session", where the results of the project were presented to around 55 participants, emphasis was on the topics of patient empowerment and the progress made with regard to addressing legal and ethical requirements related to an infrastructure in which large sets of data are shared among numerous parties. Big data issues in general were also addressed by two key note speakers from Japan and the US. The public session closed with an outlook on STaRC, the Study Trial and Research Center to be found by a core team of p-medicine under the lead of Prof. Norbert Graf.

The second part of the meeting was a closed session dedicated to the evaluation of the project by the EC. The meeting ended with a very positive assessment by the EC officer and the reviewers regarding the technical implementation of the project. They particularly stressed the excellent leadership of this 19-partner project by p-medicine’s coordinator Prof. Norbert Graf.

The EU FP7 project p-medicine was one of a number of research projects arising from the broader VPH (Virtual Physiological Human) community. Research in p-medicine was devoted to creating an infrastructure that would facilitate the translation from current practice to personalised and preventive medicine. The emphasis was on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets and building standards-compliant tools and models. Privacy, non-discrimination, and access policies were aligned to maximize protection of and benefit to patients.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
'p-medicine - From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community's 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...